Myelofibrosis historical perspective: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Myelofibrosis}}
{{Myelofibrosis}}
{{CMG}}{{AE}}{{MJK}}, {{SR}}
{{CMG}}{{AE}}{{Sab}}


==Overview==
==Overview==

Revision as of 20:38, 18 December 2018

Myelofibrosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Myelofibrosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myelofibrosis historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Myelofibrosis historical perspective

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myelofibrosis historical perspective

CDC on Myelofibrosis historical perspective

Myelofibrosis historical perspective in the news

Blogs on Myelofibrosis historical perspective

Directions to Hospitals Treating Myelofibrosis

Risk calculators and risk factors for Myelofibrosis historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sabawoon Mirwais, M.B.B.S, M.D.[2]

Overview

The first description of primary myelofibrosis (PMF) is credited to a German surgeon, Gustav Heuck, who described the concept in 1879. Additional work and discoveries started to get documented at the beginning of the twentieth century. The substantial contribution came from Max Askanazy, a German pathologist and Herbert Assmann, an Internist from Germany. The condition was given several pseudonyms before the International Working Group for Myelofibrosis Research and Treatment decided in 2006 to use the term primary myelofibrosis (PMF).

Historical Perspective

References

  1. Ansell, Stephen (2008). Rare hematological malignancies. New York, NY London: Springer. ISBN 9780387737430.
  2. 2.0 2.1 Tefferi, A (2007). "The history of myeloproliferative disorders: before and after Dameshek". Leukemia. 22 (1): 3–13. doi:10.1038/sj.leu.2404946. ISSN 0887-6924.
  3. DAMESHEK W (April 1951). "Some speculations on the myeloproliferative syndromes". Blood. 6 (4): 372–5. PMID 14820991.
  4. Tefferi A (January 2008). "The history of myeloproliferative disorders: before and after Dameshek". Leukemia. 22 (1): 3–13. doi:10.1038/sj.leu.2404946. PMID 17882283.
  5. Silverstein, Murray (1975). Agnogenic myeloid metaplasia. Acton, Mass: Pub. Sciences Group. ISBN 088416022X.

Catgeory:Oncology


Template:WikiDoc Sources